4.7 Article

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

期刊

EUROPEAN HEART JOURNAL
卷 42, 期 16, 页码 1554-1568

出版社

OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehab072

关键词

Amyloidosis; Cardiac amyloidosis; Diagnosis; Treatment; AL; TTR; Transthyretin

资金

  1. Instituto de Salud Carlos III [PI18/0765, PI20/01379]
  2. British Heart Foundation Intermediate Clinical Research Fellowship [FS/18/21/33447]
  3. National Institutes of Health [R01HL139671-01, R21AG058348, K24AG036778]

向作者/读者索取更多资源

Cardiac amyloidosis is a serious and progressive infiltrative disease caused by amyloid fibril deposition in the heart. Advances in imaging techniques and diagnostic algorithms have made it possible to diagnose the condition non-invasively. Monitoring and treating cardiac amyloidosis are important in bridging the gap between research advances and clinical practice.
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据